Shares shifted sharply higher as Hyliion jumped 7.3% to $4.25 in early trading Monday, bucking a soft broader market weighed down by rising Treasury yields and oil prices. The catalyst: Craig-Hallum started coverage on Hyliion with a "buy" rating and a $7.00 price target — implying roughly 65% upside from today's price. That bold call demands scrutiny of a company still burning cash while chasing commercialization of a novel power generator.
A New Analyst Adds Credibility — and a Second Bullish Voice Craig-Hallum isn't alone. Northland upgraded Hyliion to Outperform in August and set a $10 price target , citing progress in developing the company's fuel-flexible generator technology . A second firm piling in with a buy suggests Wall Street sees a credible path from R&D contracts to commercial revenue. Analysts have been steadily raising estimates, with the consensus earnings forecast up 6.1% over the past three months.
Military Contracts Are the Revenue Engine — For Now
Hyliion was awarded a $41.7 million U.S. Navy contract in Q2 for multi-megawatt power modules , its largest defense deal ever. Q2 revenue hit $4.9 million, up more than threefold from the year-ago period , and full-year 2026 revenue guidance was raised to roughly $15 million, a 50% increase from prior outlook . Still, the company is expected to lose $0.31 per share this year , underscoring that military R&D work funds operations but doesn't yet generate profits.
A Substantial Cash Cushion Buys Time — But Not Forever
Hyliion ended Q2 with $132.4 million in cash and investments , and now expects a year-end balance of $115–$120 million . At current quarterly losses near $12 million, that implies roughly three years of runway. The question is whether the company can begin commercial sales of its fuel-flexible generator by late 2026 as planned — engineering setbacks and manufacturing inefficiencies pose real risks to that timeline .
The $7 Target Hinges on What Hasn't Happened Yet
Hyliion holds non-binding letters of intent for nearly 750 generator units worth more than $400 million in potential revenue . But "non-binding" and "potential" are doing heavy lifting. With a market cap near $831 million as of mid-August — up over 200% in a year — investors are already pricing in significant success. Craig-Hallum's $7 target asks them to pay more for a company whose commercial product hasn't shipped yet. The upgrade validates the thesis; execution will validate the stock.